Goflikicept
- Generic Name
- Goflikicept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2416984-26-2
- Unique Ingredient Identifier
- 11DRN01OK2
- Background
Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov-2) Infection (COVID-19)).
- Associated Conditions
- -
- Associated Therapies
- -
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
- Conditions
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT05673902
- Locations
- π·πΊ
National medical research center named after V. A. Almazov, Saint Petersburg, Russian Federation
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm International, LLC
- Registration Number
- NCT05432960
- Locations
- π·πΊ
FGBU "National Medical Research Center named after V.A. Almazov", Ministry of Health of the Russian Federation, Department of Rheumatology, St. Petersburg, Russian Federation
π·πΊState Budgetary Institution of Healthcare Leningrad Regional Clinical Hospital, Department of Rheumatology, St. Petersburg, Russian Federation
π·πΊResearch Institute of Rheumatology. V.A. Nasonova, Moscow, Russian Federation
Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05190991
- Locations
- π¦π²
Center of Medical Genetics and Primary Health Care LLC, Yerevan, Armenia
π·πΊFSBEI HE First Moscow State Medical University named after I.M. Sechenov, Moscow, Russian Federation
π·πΊMoscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin, Moscow, Russian Federation
Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- R-Pharm Overseas, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05107934
- Locations
- πΊπΈ
Virginia Commonwealth University, Richmond, Virginia, United States
Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT05092776
- Locations
- π·πΊ
Saint-Petersburg Pasteur Institute, Saint-Petersburg, Russian Federation
π·πΊTerafarm, Llc, Stavropol, Russian Federation
πΉπ·Hacettepe University Faculty of Medicine, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.